Photo of Dennis C. Sgroi, MD

Dennis C. Sgroi, MD

  • Associate Pathologist
  • Subspecialty co-Head, Breast Pathology Service
  • Professor of Pathology, Harvard Medical School


Accepting New Patients

E-mail me Visit my website


Dr. Sgroi is working to find better ways to identify patients who are at risk for developing breast cancer and to identify those who are likely to benefit from targeted drug therapies.



Centers & Specialties

Cancer Center

Clinical Interests
  • Breast pathology
Medical Education
  • MD, University of Connecticut School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Anatomic Pathology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Dr. Sgroi is the subspecialty co-head of Breast Pathology at the Massachusetts General Hospital. Dr Sgroi received his undergraduate degree from Bowdoin College and his medical degree from the University of Connecticut School of Medicine. After completing a residency in anatomic pathology at Massachusetts General Hospital, Dr. Sgroi completed a postdoctoral research fellowship in molecular pathology under the direction of Dr. Ivan Stamenkovic at Massachusetts General Hospital. He is a member and principal investigator in the Molecular Pathology Research Unit and Center for Cancer Research. The Sgroi Lab investigates the molecular genetic basis of human breast cancer and has utilized gene expression and proteomic technologies to better understand breast cancer progression.

Edit Profile

Research & Publications

Research Summary

Human Breast Cancer Anti-Hormonal Resistance: Dr. Sgroi has shown that gene expression alterations are powerful predictors of breast cancer outcome and therapeutic response. His laboratory has focused on determining the clinical utility of the HOXB13:IL17BR and MGI biomarkers in estrogen receptor-positive, lymph node negative breast cancer patients, and understanding the molecular functional role of HOXB13 and IL17BR as it relates to anti-hormonal therapeutic response. Dr. Sgroi is also affiliated with the Dana-Farber/Harvard Cancer Center?s Breast Cancer and Cancer Genetics programs. Find more information on the Sgroi Lab website, or read about Dr. Sgroi's research in the 2014 annual report of the Center for Cancer Research. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Sgroi's profile page at the Harvard Clinical and Translational Science Center.


View my most recent publications at PubMed

  1. Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. Olsen L, Campos B, Winther O, Sgroi DC, Karger BL, Brusic V. BMC Med Genomics. 2014 Dec 8;7 Suppl 3:S2. doi: 10.1186/1755-8794-7-S3-S2. Epub 2014 Dec 8.
  2. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME; NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW. BMC Cancer. 2014 Nov 26;14:884. doi: 10.1186/1471-2407-14-884.
  3. VAV3 mediates resistance to breast cancer endocrine therapy. Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, P?rez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, Garc?a N, Bonifaci N, Climent F, Soler MT, Rodr?guez-Vida A, Gil M, Brunet J, Martrat G, G?mez-Bald? L, Extremera AI, Figueras A, et al.

Edit Profile

News & Events

  • Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence

    A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.


149 13th Street
Charlestown MA, 02129-2020
Phone: 617-726-5697
Fax: 617-726-5684

Edit Profile

Back to Top